关键词：传染性疾病；抗感染类药物；杀死；抑制微生物
摘 要：Human beings are susceptible to various kinds of infection that have adverse effects on their health. Infectious diseases are caused by various pathogens such as bacteria, fungi, parasites, or viruses and are contagious and spread by direct or indirect contact. Anti-infective drugs act by killing or inhibiting the growth of the microorganisms. These drugs act via the host defense system or by directly targeting the causative agent. On the basis of the target organism, these drugs can be classified as anti-bacterial, anti-viral, anti-fungal, and anti-parasitic drugs.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.2.1 Market Penetration

06.2.2 Marketing Approvals

06.2.3 Patent Protection

06.2.4 Regulatory Designation

06.2.5 Orphan Drug Designation

06.2.6 WHO Recognition

06.2.7 Other Factors

06.3 Five Forces Analysis

07. Epidemiology

07.1 Viral Infections

07.2 Fungal Infections

07.3 Bacterial Infections

07.4 Parasitic Infections

08. Market Segmentation by Type of Drug

08.1 Anti-bacterial Drugs

08.1.1 Anti-bacterial Drugs Market in US

08.2 Anti-viral Drugs

08.2.1 Anti-viral Drugs Market in US

08.3 Anti-fungal Drugs

08.3.1 Anti-fungal Drugs Market in US

08.4 Anti-parasitic Drugs

08.4.1 Anti-parasitic Drugs Market in US

09. Market Segmentation by Route of

Administration

09.1 Oral

09.2 Parenteral

09.3 Topical

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

17.1 Competitive Scenario

17.1.1 Key News

17.1.2 Mergers and Acquisitions

17.2 Market Share Analysis 2014

17.2.1 Gilead Sciences

17.2.2 Johnson & Johnson

17.2.3 Merck

17.2.4 Pfizer

17.2.5 F. Hoffmann-La Roche

17.2.6 GlaxoSmithKline

17.3 Other and Future Prominent Vendors

18. Key Vendor Analysis

18.1 F. Hoffmann-La Roche Ltd.

18.1.1 Key Facts

18.1.2 Business Overview

18.1.3 Business Segmentation

18.1.4 Business Segmentation by Revenue 2012 and 2013

18.1.5 Sales by Geography

18.1.6 Business Strategy

18.1.7 Key Information

18.1.8 SWOT Analysis

18.2 Gilead Sciences

18.2.1 Key Facts

18.2.2 Business Overview

18.2.3 Geographical Segmentation by Revenue 2013

18.2.4 Recent Developments

18.2.5 SWOT Analysis

18.3 GlaxoSmithKline

18.3.1 Key Facts

18.3.2 Business Overview

18.3.3 Business Segmentation by Revenue 2014

18.3.4 Business Segmentation by Revenue 2013 and 2014

18.3.5 Geographical Segmentation by Revenue 2014

18.3.6 Business Strategy

18.3.7 Recent Developments

18.3.8 SWOT Analysis

18.4 Johnson & Johnson

18.4.1 Key Facts

18.4.2 Business Overview

18.4.3 Business Segmentation by Revenue 2014

18.4.4 Business Segmentation by Revenue 2013 and 2014

18.4.5 Geographical Segmentation by Revenue 2014

18.4.6 Business Strategy

18.4.7 Recent Developments

18.4.8 SWOT Analysis

18.5 Merck

18.5.1 Key Facts

18.5.2 Business Overview

18.5.3 Business Segmentation by Revenue 2013

18.5.4 Business Segmentation by Revenue 2012 and 2013

18.5.5 Sales by Geography

18.5.6 Business Strategy

18.5.7 Key Developments

18.5.8 SWOT Analysis

18.6 Pfizer

18.6.1 Key Facts

18.6.2 Business Overview

18.6.3 Business Segmentation by Revenue 2014

18.6.4 Business Segmentation by Revenue 2013 and 2014

18.6.5 Geographical Segmentation by Revenue 2014

18.6.6 Business Strategy

18.6.7 Key Developments

18.6.8 SWOT Analysis

19. Other Reports in this Series